Mologic’s infection test for dialysis patients bags CE mark

nephrons
Mologic's test is designed to catch peritoneal infection early so patients can avoid further complications. (Lindstrom et al CC-BY 4.0)

U.K.-based Mologic has earned a CE mark for a point-of-care test that screens peritoneal dialysis patients for infection. The test, designed for at-home use, rapidly warns patients and caregivers of infection.

Unlike hemodialysis, which uses an external filter to clean the blood, peritoneal dialysis uses the peritoneum—the membrane that lines the inside of the abdomen—as a natural filter. Hemodialysis may be performed at a dialysis center, hospital or at home, but it requires patients to be connected to a dialysis machine for hours at a time, multiple times a week. Patients on peritoneal dialysis may be treated while they go about their daily activities, or at night, while they sleep.

Both types of dialysis require an access point. Peritoneal dialysis patients will have a catheter surgically placed in the chest or abdomen ahead of treatment. Patients with catheters in their abdomen are more prone to peritonitis, a serious infection that requires antibiotic treatment. Quick treatment is crucial in warding off further problems, including damage to the peritoneal membrane.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Physician payment reform has made home dialysis less popular: Study

Current tests can take longer than 24 hours to diagnose infection, while Mologic’s Periplex test returns results in 10 minutes, the company said in a statement. It detects two infection biomarkers in waste fluid from peritoneal dialysis. If given a positive result, a patient may then promptly seek care.

The company also announced the test's commercial launch in the statement.

“PERiPLEX is the first of a pipeline of products from Mologic to receive CE mark approval. We are developing similar diagnostic tests for a range of disease areas, including sepsis, urinary tract infections and chronic obstructive pulmonary disease (COPD),” said CEO Mark Davis in the statement. “Each of these tests use lateral flow immunoassay technology to detect a host inflammatory response, for rapid, point-of-care diagnosis and, importantly, to enable earlier treatment for patients.”

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Exact Sciences received an FDA breakthrough designation for its liver cancer blood test as it finalized its $2.8 billion merger with Genomic Health.